MOONLAKE IMMUNOTHERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.49 USD | +0.57% |
|
+0.71% | -29.64% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.67B |
|---|---|---|---|---|---|
| Net income 2024 * | -70M | Net income 2025 * | -100M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 509M | Net cash position 2025 * | 436M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-38.9
x | P/E ratio 2025 * |
-26
x | Employees | 50 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.58% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.57% | ||
| 1 week | +0.71% | ||
| Current month | -15.41% | ||
| 1 month | -15.16% | ||
| 3 months | -25.69% | ||
| 6 months | -17.58% | ||
| Current year | -29.64% |
1 week
40.72
43.60
1 month
40.6852.92
Current year
40.6864.98
1 year
20.3564.98
3 years
4.2564.98
5 years
4.2564.98
10 years
4.2564.98
| Managers | Title | Age | Since |
|---|---|---|---|
Jorge da Silva
FOU | Founder | 47 | 22-04-04 |
Kristian Reich
FOU | Founder | 58 | 22-04-04 |
| Director of Finance/CFO | 36 | 22-04-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Sturge
CHM | Chairman | 65 | 22-04-04 |
| Director/Board Member | 64 | 22-04-04 | |
Spike N. Loy
BRD | Director/Board Member | 43 | 22-04-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.23% | 4 M€ | -5.15% | - | |
| 1.06% | 5 M€ | +8.63% | ||
| 0.02% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 42.49 | +0.57% | 223,585 |
| 24-04-25 | 42.25 | -0.42% | 264,856 |
| 24-04-24 | 42.43 | -1.90% | 273,377 |
| 24-04-23 | 43.25 | +5.44% | 579,345 |
| 24-04-22 | 41.02 | -2.77% | 276,690 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
42.49
USD
Average target price
73.38
USD
Spread / Average Target
+72.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.64% | 2.67B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MLTX Stock
